BR112013002533A2 - Polipeptídeo de ligação de proteína sérica e diacorpo complexado ao polipeptídeo de ligação de proteína sérica - Google Patents

Info

Publication number

BR112013002533A2

BR112013002533A2 BR112013002533-6A BR112013002533A BR112013002533A2 BR 112013002533 A2 BR112013002533 A2 BR 112013002533A2 BR 112013002533 A BR112013002533 A BR 112013002533A BR 112013002533 A2 BR112013002533 A2 BR 112013002533A2

Authority

BR

Brazil

Prior art keywords

domain

binding

diabody

polypeptide

seq

Prior art date

2010-08-02

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 298
• 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 289
• 229920001184 polypeptide Polymers 0.000 title claims abstract description 282
• 210000002966 serum Anatomy 0.000 title claims description 13
• 230000027455 binding Effects 0.000 claims abstract description 428
• 239000000427 antigen Substances 0.000 claims abstract description 199
• 108091007433 antigens Proteins 0.000 claims abstract description 197
• 102000036639 antigens Human genes 0.000 claims abstract description 197
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 70
• 102000004506 Blood Proteins Human genes 0.000 claims abstract description 9
• 108010017384 Blood Proteins Proteins 0.000 claims abstract description 9
• 241000282414 Homo sapiens Species 0.000 claims description 202
• 108060003951 Immunoglobulin Proteins 0.000 claims description 91
• 102000018358 immunoglobulin Human genes 0.000 claims description 91
• 102000005962 receptors Human genes 0.000 claims description 82
• 108020003175 receptors Proteins 0.000 claims description 82
• 201000011510 cancer Diseases 0.000 claims description 43
• 102000014914 Carrier Proteins Human genes 0.000 claims description 42
• 108091008324 binding proteins Proteins 0.000 claims description 42
• 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims description 38
• 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims description 37
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 26
• 108091008874 T cell receptors Proteins 0.000 claims description 16
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 16
• 238000001727 in vivo Methods 0.000 claims description 16
• 206010006187 Breast cancer Diseases 0.000 claims description 7
• 208000026310 Breast neoplasm Diseases 0.000 claims description 7
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 7
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 7
• 108091006027 G proteins Proteins 0.000 claims description 5
• 102000030782 GTP binding Human genes 0.000 claims description 5
• 108091000058 GTP-Binding Proteins 0.000 claims description 5
• 206010005003 Bladder cancer Diseases 0.000 claims description 4
• 206010009944 Colon cancer Diseases 0.000 claims description 4
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 4
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 4
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
• 108010075348 Activated-Leukocyte Cell Adhesion Molecule Proteins 0.000 claims description 2
• 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 2
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
• 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
• 102100024210 CD166 antigen Human genes 0.000 claims description 2
• 102100027207 CD27 antigen Human genes 0.000 claims description 2
• 108010045374 CD36 Antigens Proteins 0.000 claims description 2
• 101150013553 CD40 gene Proteins 0.000 claims description 2
• 108090000007 Carboxypeptidase M Proteins 0.000 claims description 2
• 102100032936 Carboxypeptidase M Human genes 0.000 claims description 2
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 2
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
• 102100024361 Disintegrin and metalloproteinase domain-containing protein 9 Human genes 0.000 claims description 2
• 101710116121 Disintegrin and metalloproteinase domain-containing protein 9 Proteins 0.000 claims description 2
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
• 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 2
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
• 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 2
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 2
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 2
• 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 2
• 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims description 2
• 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 2
• 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 2
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
• 101000964453 Homo sapiens Zinc finger protein 354C Proteins 0.000 claims description 2
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 2
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 2
• 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 2
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims description 2
• 108010040135 Junctional Adhesion Molecule C Proteins 0.000 claims description 2
• 102100023429 Junctional adhesion molecule C Human genes 0.000 claims description 2
• 102000005712 Keratin-8 Human genes 0.000 claims description 2
• 108010070511 Keratin-8 Proteins 0.000 claims description 2
• 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
• 102100039373 Membrane cofactor protein Human genes 0.000 claims description 2
• 108010008707 Mucin-1 Proteins 0.000 claims description 2
• 102100034256 Mucin-1 Human genes 0.000 claims description 2
• 208000034578 Multiple myelomas Diseases 0.000 claims description 2
• 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 2
• 102000004140 Oncostatin M Human genes 0.000 claims description 2
• 108090000630 Oncostatin M Proteins 0.000 claims description 2
• 206010033128 Ovarian cancer Diseases 0.000 claims description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
• 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 claims description 2
• 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
• 206010060862 Prostate cancer Diseases 0.000 claims description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
• 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
• 206010057644 Testis cancer Diseases 0.000 claims description 2
• 108010033576 Transferrin Receptors Proteins 0.000 claims description 2
• 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims description 2
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
• 108091008605 VEGF receptors Proteins 0.000 claims description 2
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 2
• 102100040311 Zinc finger protein 354C Human genes 0.000 claims description 2
• 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 2
• 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 2
• 201000010881 cervical cancer Diseases 0.000 claims description 2
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
• 208000029742 colonic neoplasm Diseases 0.000 claims description 2
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 2
• 208000005017 glioblastoma Diseases 0.000 claims description 2
• 108010044426 integrins Proteins 0.000 claims description 2
• 102000006495 integrins Human genes 0.000 claims description 2
• 201000005202 lung cancer Diseases 0.000 claims description 2
• 208000020816 lung neoplasm Diseases 0.000 claims description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
• 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
• 201000003120 testicular cancer Diseases 0.000 claims description 2
• 125000006850 spacer group Chemical group 0.000 claims 7
• 102000009027 Albumins Human genes 0.000 claims 5
• 108010088751 Albumins Proteins 0.000 claims 5
• 101800000194 Growth hormone-binding protein Proteins 0.000 claims 4
• 102400001066 Growth hormone-binding protein Human genes 0.000 claims 4
• 102000049320 CD36 Human genes 0.000 claims 1
• 102000016362 Catenins Human genes 0.000 claims 1
• 108010067316 Catenins Proteins 0.000 claims 1
• 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 1
• 102100039717 G antigen 1 Human genes 0.000 claims 1
• 101000886137 Homo sapiens G antigen 1 Proteins 0.000 claims 1
• 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 claims 1
• 108010056664 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase Proteins 0.000 claims 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
• 241000194017 Streptococcus Species 0.000 claims 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract description 54
• 238000011282 treatment Methods 0.000 abstract description 10
• 208000015181 infectious disease Diseases 0.000 abstract description 7
• 208000035473 Communicable disease Diseases 0.000 abstract description 5
• 208000037765 diseases and disorders Diseases 0.000 abstract description 4
• 208000026278 immune system disease Diseases 0.000 abstract description 2
• 230000035987 intoxication Effects 0.000 abstract 1
• 231100000566 intoxication Toxicity 0.000 abstract 1
• 210000004027 cell Anatomy 0.000 description 297
• 238000000034 method Methods 0.000 description 135
• 108090000623 proteins and genes Proteins 0.000 description 106
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 90
• 235000001014 amino acid Nutrition 0.000 description 87
• 102000004169 proteins and genes Human genes 0.000 description 85
• 125000003275 alpha amino acid group Chemical group 0.000 description 84
• 235000018102 proteins Nutrition 0.000 description 79
• 238000003556 assay Methods 0.000 description 75
• 230000001404 mediated effect Effects 0.000 description 75
• 239000012636 effector Substances 0.000 description 70
• 230000000694 effects Effects 0.000 description 61
• 229940024606 amino acid Drugs 0.000 description 60
• 150000001413 amino acids Chemical class 0.000 description 59
• 238000006467 substitution reaction Methods 0.000 description 53
• 230000006870 function Effects 0.000 description 51
• 230000003993 interaction Effects 0.000 description 49
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 44
• 210000004899 c-terminal region Anatomy 0.000 description 44
• 230000014509 gene expression Effects 0.000 description 42
• 238000004458 analytical method Methods 0.000 description 39
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 36
• 108010087819 Fc receptors Proteins 0.000 description 34
• 102000009109 Fc receptors Human genes 0.000 description 33
• 125000005647 linker group Chemical group 0.000 description 33
• 230000011664 signaling Effects 0.000 description 33
• 239000003814 drug Substances 0.000 description 32
• 230000026731 phosphorylation Effects 0.000 description 32
• 238000006366 phosphorylation reaction Methods 0.000 description 32
• 125000000539 amino acid group Chemical group 0.000 description 30
• 230000001419 dependent effect Effects 0.000 description 30
• 230000005764 inhibitory process Effects 0.000 description 30
• 210000003630 histaminocyte Anatomy 0.000 description 28
• 239000012634 fragment Substances 0.000 description 27
• 125000003729 nucleotide group Chemical group 0.000 description 27
• 241000699666 Mus <mouse, genus> Species 0.000 description 26
• 230000004913 activation Effects 0.000 description 26
• 238000001994 activation Methods 0.000 description 26
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
• 239000003446 ligand Substances 0.000 description 26
• 210000001616 monocyte Anatomy 0.000 description 26
• 239000002773 nucleotide Substances 0.000 description 26
• 108091008875 B cell receptors Proteins 0.000 description 25
• 206010057249 Phagocytosis Diseases 0.000 description 25
• 230000008782 phagocytosis Effects 0.000 description 25
• 239000003795 chemical substances by application Substances 0.000 description 24
• 230000004048 modification Effects 0.000 description 23
• 238000012986 modification Methods 0.000 description 23
• 238000002965 ELISA Methods 0.000 description 21
• 241000699670 Mus sp. Species 0.000 description 21
• 210000002540 macrophage Anatomy 0.000 description 21
• 102000037865 fusion proteins Human genes 0.000 description 20
• 108020001507 fusion proteins Proteins 0.000 description 20
• 210000000822 natural killer cell Anatomy 0.000 description 20
• 108020004414 DNA Proteins 0.000 description 19
• 230000000295 complement effect Effects 0.000 description 19
• 230000002401 inhibitory effect Effects 0.000 description 19
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 19
• 229940124597 therapeutic agent Drugs 0.000 description 19
• 230000015572 biosynthetic process Effects 0.000 description 17
• 150000007523 nucleic acids Chemical class 0.000 description 17
• 238000003018 immunoassay Methods 0.000 description 16
• 230000004044 response Effects 0.000 description 16
• 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 15
• 210000001744 T-lymphocyte Anatomy 0.000 description 15
• 238000012512 characterization method Methods 0.000 description 15
• -1 for example Proteins 0.000 description 15
• 230000035772 mutation Effects 0.000 description 15
• 230000001225 therapeutic effect Effects 0.000 description 15
• 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 14
• 102000009490 IgG Receptors Human genes 0.000 description 14
• 108010073807 IgG Receptors Proteins 0.000 description 14
• 238000000375 direct analysis in real time Methods 0.000 description 14
• 201000010099 disease Diseases 0.000 description 14
• 238000012063 dual-affinity re-targeting Methods 0.000 description 14
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 14
• 238000000338 in vitro Methods 0.000 description 14
• 238000010561 standard procedure Methods 0.000 description 14
• 238000004220 aggregation Methods 0.000 description 13
• 238000001514 detection method Methods 0.000 description 13
• 239000000539 dimer Substances 0.000 description 13
• 239000013604 expression vector Substances 0.000 description 13
• 210000004408 hybridoma Anatomy 0.000 description 13
• 230000001976 improved effect Effects 0.000 description 13
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 13
• 102000039446 nucleic acids Human genes 0.000 description 13
• 108020004707 nucleic acids Proteins 0.000 description 13
• 230000001717 pathogenic effect Effects 0.000 description 13
• 238000002823 phage display Methods 0.000 description 13
• 230000000069 prophylactic effect Effects 0.000 description 13
• 210000001519 tissue Anatomy 0.000 description 13
• 239000013598 vector Substances 0.000 description 13
• 208000023275 Autoimmune disease Diseases 0.000 description 12
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 12
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 12
• 241001529936 Murinae Species 0.000 description 12
• 208000035475 disorder Diseases 0.000 description 12
• 238000005516 engineering process Methods 0.000 description 12
• 238000000746 purification Methods 0.000 description 12
• 239000000126 substance Substances 0.000 description 12
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 11
• 241000588724 Escherichia coli Species 0.000 description 11
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 11
• 241000700605 Viruses Species 0.000 description 11
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 11
• 102000004190 Enzymes Human genes 0.000 description 10
• 108090000790 Enzymes Proteins 0.000 description 10
• 230000003213 activating effect Effects 0.000 description 10
• 229940088598 enzyme Drugs 0.000 description 10
• 238000001990 intravenous administration Methods 0.000 description 10
• 238000003259 recombinant expression Methods 0.000 description 10
• 230000007115 recruitment Effects 0.000 description 10
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 9
• 210000004369 blood Anatomy 0.000 description 9
• 239000008280 blood Substances 0.000 description 9
• 238000003776 cleavage reaction Methods 0.000 description 9
• 229940072221 immunoglobulins Drugs 0.000 description 9
• 239000000178 monomer Substances 0.000 description 9
• 210000000440 neutrophil Anatomy 0.000 description 9
• 108091033319 polynucleotide Proteins 0.000 description 9
• 102000040430 polynucleotide Human genes 0.000 description 9
• 239000002157 polynucleotide Substances 0.000 description 9
• 230000007017 scission Effects 0.000 description 9
• 230000019491 signal transduction Effects 0.000 description 9
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 9
• 102000004127 Cytokines Human genes 0.000 description 8
• 108090000695 Cytokines Proteins 0.000 description 8
• 241001465754 Metazoa Species 0.000 description 8
• 108091028043 Nucleic acid sequence Proteins 0.000 description 8
• 230000020411 cell activation Effects 0.000 description 8
• 230000001413 cellular effect Effects 0.000 description 8
• 238000006243 chemical reaction Methods 0.000 description 8
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 8
• 230000009089 cytolysis Effects 0.000 description 8
• 238000013461 design Methods 0.000 description 8
• 229940079593 drug Drugs 0.000 description 8
• 230000001965 increasing effect Effects 0.000 description 8
• 238000004519 manufacturing process Methods 0.000 description 8
• 239000013612 plasmid Substances 0.000 description 8
• 239000000523 sample Substances 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 241000283707 Capra Species 0.000 description 7
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 7
• 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 7
• 241000283973 Oryctolagus cuniculus Species 0.000 description 7
• 108010076039 Polyproteins Proteins 0.000 description 7
• 230000009824 affinity maturation Effects 0.000 description 7
• 230000004663 cell proliferation Effects 0.000 description 7
• 230000003013 cytotoxicity Effects 0.000 description 7
• 231100000135 cytotoxicity Toxicity 0.000 description 7
• 230000013595 glycosylation Effects 0.000 description 7
• 238000006206 glycosylation reaction Methods 0.000 description 7
• 238000011813 knockout mouse model Methods 0.000 description 7
• 210000000265 leukocyte Anatomy 0.000 description 7
• 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 7
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
• 241000894007 species Species 0.000 description 7
• 210000004881 tumor cell Anatomy 0.000 description 7
• 241000701161 unidentified adenovirus Species 0.000 description 7
• 230000003612 virological effect Effects 0.000 description 7
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 6
• 102100030931 Ladinin-1 Human genes 0.000 description 6
• 102000043136 MAP kinase family Human genes 0.000 description 6
• 108091054455 MAP kinase family Proteins 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 238000007792 addition Methods 0.000 description 6
• 230000001580 bacterial effect Effects 0.000 description 6
• 230000004071 biological effect Effects 0.000 description 6
• 239000000872 buffer Substances 0.000 description 6
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 230000001086 cytosolic effect Effects 0.000 description 6
• 238000010494 dissociation reaction Methods 0.000 description 6
• 230000005593 dissociations Effects 0.000 description 6
• 210000003979 eosinophil Anatomy 0.000 description 6
• MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 6
• 230000001900 immune effect Effects 0.000 description 6
• 238000003780 insertion Methods 0.000 description 6
• 230000037431 insertion Effects 0.000 description 6
• 230000003834 intracellular effect Effects 0.000 description 6
• 238000002955 isolation Methods 0.000 description 6
• 230000002147 killing effect Effects 0.000 description 6
• 230000000670 limiting effect Effects 0.000 description 6
• 238000013507 mapping Methods 0.000 description 6
• 238000002703 mutagenesis Methods 0.000 description 6
• 231100000350 mutagenesis Toxicity 0.000 description 6
• 229920001542 oligosaccharide Polymers 0.000 description 6
• 150000002482 oligosaccharides Chemical class 0.000 description 6
• 239000002245 particle Substances 0.000 description 6
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
• 239000002243 precursor Substances 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 238000003118 sandwich ELISA Methods 0.000 description 6
• 238000012216 screening Methods 0.000 description 6
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
• 230000004936 stimulating effect Effects 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• 241000894006 Bacteria Species 0.000 description 5
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 101100334515 Homo sapiens FCGR3A gene Proteins 0.000 description 5
• 108020003285 Isocitrate lyase Proteins 0.000 description 5
• 101710177601 Ladinin-1 Proteins 0.000 description 5
• 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 5
• 241000710886 West Nile virus Species 0.000 description 5
• 230000001363 autoimmune Effects 0.000 description 5
• 210000003651 basophil Anatomy 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 229960002685 biotin Drugs 0.000 description 5
• 235000020958 biotin Nutrition 0.000 description 5
• 239000011616 biotin Substances 0.000 description 5
• 239000011575 calcium Substances 0.000 description 5
• 230000003915 cell function Effects 0.000 description 5
• 239000011651 chromium Substances 0.000 description 5
• 238000010276 construction Methods 0.000 description 5
• 230000008878 coupling Effects 0.000 description 5
• 238000010168 coupling process Methods 0.000 description 5
• 238000005859 coupling reaction Methods 0.000 description 5
• 230000016396 cytokine production Effects 0.000 description 5
• 238000012217 deletion Methods 0.000 description 5
• 230000037430 deletion Effects 0.000 description 5
• 239000002158 endotoxin Substances 0.000 description 5
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 5
• 210000004602 germ cell Anatomy 0.000 description 5
• 230000002519 immonomodulatory effect Effects 0.000 description 5
• 210000000987 immune system Anatomy 0.000 description 5
• 230000036039 immunity Effects 0.000 description 5
• 230000005847 immunogenicity Effects 0.000 description 5
• 238000002372 labelling Methods 0.000 description 5
• 229920006008 lipopolysaccharide Polymers 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 230000002285 radioactive effect Effects 0.000 description 5
• 238000012552 review Methods 0.000 description 5
• 230000009870 specific binding Effects 0.000 description 5
• 239000000758 substrate Substances 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• 238000001262 western blot Methods 0.000 description 5
• 208000016557 Acute basophilic leukemia Diseases 0.000 description 4
• 230000003844 B-cell-activation Effects 0.000 description 4
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 4
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 4
• 102000000844 Cell Surface Receptors Human genes 0.000 description 4
• 108010001857 Cell Surface Receptors Proteins 0.000 description 4
• 102100037832 Docking protein 1 Human genes 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
• 102000005720 Glutathione transferase Human genes 0.000 description 4
• 108010070675 Glutathione transferase Proteins 0.000 description 4
• 108091006905 Human Serum Albumin Proteins 0.000 description 4
• 102000008100 Human Serum Albumin Human genes 0.000 description 4
• 241000725303 Human immunodeficiency virus Species 0.000 description 4
• 108010073816 IgE Receptors Proteins 0.000 description 4
• 102000009438 IgE Receptors Human genes 0.000 description 4
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
• 206010025323 Lymphomas Diseases 0.000 description 4
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 4
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 4
• 241000699660 Mus musculus Species 0.000 description 4
• 241001494479 Pecora Species 0.000 description 4
• 241000700159 Rattus Species 0.000 description 4
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
• 102100040247 Tumor necrosis factor Human genes 0.000 description 4
• 230000021736 acetylation Effects 0.000 description 4
• 238000006640 acetylation reaction Methods 0.000 description 4
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
• 229910052791 calcium Inorganic materials 0.000 description 4
• 230000030833 cell death Effects 0.000 description 4
• 230000024245 cell differentiation Effects 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 230000021615 conjugation Effects 0.000 description 4
• 238000004132 cross linking Methods 0.000 description 4
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
• 231100000599 cytotoxic agent Toxicity 0.000 description 4
• 230000034994 death Effects 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 210000004443 dendritic cell Anatomy 0.000 description 4
• 238000004090 dissolution Methods 0.000 description 4
• 230000007783 downstream signaling Effects 0.000 description 4
• 210000003743 erythrocyte Anatomy 0.000 description 4
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
• 238000002825 functional assay Methods 0.000 description 4
• 230000004927 fusion Effects 0.000 description 4
• 239000008187 granular material Substances 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 230000036541 health Effects 0.000 description 4
• 238000005734 heterodimerization reaction Methods 0.000 description 4
• 238000009396 hybridization Methods 0.000 description 4
• 230000002163 immunogen Effects 0.000 description 4
• 238000000099 in vitro assay Methods 0.000 description 4
• 238000011534 incubation Methods 0.000 description 4
• 208000027866 inflammatory disease Diseases 0.000 description 4
• 108091008042 inhibitory receptors Proteins 0.000 description 4
• 239000002609 medium Substances 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 238000011275 oncology therapy Methods 0.000 description 4
• 239000011886 peripheral blood Substances 0.000 description 4
• 210000005259 peripheral blood Anatomy 0.000 description 4
• 210000001539 phagocyte Anatomy 0.000 description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
• 230000035755 proliferation Effects 0.000 description 4
• 239000012857 radioactive material Substances 0.000 description 4
• 230000006798 recombination Effects 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 231100000205 reproductive and developmental toxicity Toxicity 0.000 description 4
• 239000011347 resin Substances 0.000 description 4
• 229920005989 resin Polymers 0.000 description 4
• 238000001338 self-assembly Methods 0.000 description 4
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
• 238000001542 size-exclusion chromatography Methods 0.000 description 4
• 210000000130 stem cell Anatomy 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 239000003053 toxin Substances 0.000 description 4
• 238000011830 transgenic mouse model Methods 0.000 description 4
• 230000014616 translation Effects 0.000 description 4
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 3
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
• 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 3
• 231100000699 Bacterial toxin Toxicity 0.000 description 3
• 208000011691 Burkitt lymphomas Diseases 0.000 description 3
• 229940124292 CD20 monoclonal antibody Drugs 0.000 description 3
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 3
• 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 3
• 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• 108091035707 Consensus sequence Proteins 0.000 description 3
• 239000004971 Cross linker Substances 0.000 description 3
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
• 108010092160 Dactinomycin Proteins 0.000 description 3
• 238000012286 ELISA Assay Methods 0.000 description 3
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 3
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 3
• 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 3
• 206010061218 Inflammation Diseases 0.000 description 3
• 102000004388 Interleukin-4 Human genes 0.000 description 3
• 108090000978 Interleukin-4 Proteins 0.000 description 3
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 101150024075 Mapk1 gene Proteins 0.000 description 3
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
• OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
• MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 230000002494 anti-cea effect Effects 0.000 description 3
• 230000000890 antigenic effect Effects 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 208000037979 autoimmune inflammatory disease Diseases 0.000 description 3
• 239000000688 bacterial toxin Substances 0.000 description 3
• 230000001588 bifunctional effect Effects 0.000 description 3
• 238000013357 binding ELISA Methods 0.000 description 3
• 230000008512 biological response Effects 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 210000001772 blood platelet Anatomy 0.000 description 3
• 238000009395 breeding Methods 0.000 description 3
• 230000001488 breeding effect Effects 0.000 description 3
• 150000001720 carbohydrates Chemical group 0.000 description 3
• 230000006369 cell cycle progression Effects 0.000 description 3
• 230000006037 cell lysis Effects 0.000 description 3
• 210000000170 cell membrane Anatomy 0.000 description 3
• 239000002458 cell surface marker Substances 0.000 description 3
• 230000005890 cell-mediated cytotoxicity Effects 0.000 description 3
• 239000011248 coating agent Substances 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 238000012875 competitive assay Methods 0.000 description 3
• 239000002299 complementary DNA Substances 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 230000009260 cross reactivity Effects 0.000 description 3
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 230000004069 differentiation Effects 0.000 description 3
• 238000010790 dilution Methods 0.000 description 3
• 239000012895 dilution Substances 0.000 description 3
• 238000006471 dimerization reaction Methods 0.000 description 3
• 230000009977 dual effect Effects 0.000 description 3
• 238000010828 elution Methods 0.000 description 3
• 230000002349 favourable effect Effects 0.000 description 3
• 238000000684 flow cytometry Methods 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
• 229960001340 histamine Drugs 0.000 description 3
• 229940127121 immunoconjugate Drugs 0.000 description 3
• 230000016784 immunoglobulin production Effects 0.000 description 3
• 238000001114 immunoprecipitation Methods 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 230000004054 inflammatory process Effects 0.000 description 3
• 238000012933 kinetic analysis Methods 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 208000000516 mast-cell leukemia Diseases 0.000 description 3
• 201000008749 mast-cell sarcoma Diseases 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• 229910021645 metal ion Inorganic materials 0.000 description 3
• 239000010445 mica Substances 0.000 description 3
• 229910052618 mica group Inorganic materials 0.000 description 3
• 239000000203 mixture Substances 0.000 description 3
• 238000010369 molecular cloning Methods 0.000 description 3
• 210000005087 mononuclear cell Anatomy 0.000 description 3
• 210000000066 myeloid cell Anatomy 0.000 description 3
• 229950006780 n-acetylglucosamine Drugs 0.000 description 3
• 230000003472 neutralizing effect Effects 0.000 description 3
• 230000014207 opsonization Effects 0.000 description 3
• 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 3
• 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 3
• 230000000242 pagocytic effect Effects 0.000 description 3
• 230000001323 posttranslational effect Effects 0.000 description 3
• 238000001556 precipitation Methods 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 230000006337 proteolytic cleavage Effects 0.000 description 3
• 238000003127 radioimmunoassay Methods 0.000 description 3
• 238000005215 recombination Methods 0.000 description 3
• 229960004641 rituximab Drugs 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 229940076279 serotonin Drugs 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 239000007790 solid phase Substances 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 229940126585 therapeutic drug Drugs 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• 230000002103 transcriptional effect Effects 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 239000002699 waste material Substances 0.000 description 3
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
• VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 2
• UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
• 108010032595 Antibody Binding Sites Proteins 0.000 description 2
• 108090001008 Avidin Proteins 0.000 description 2
• 244000025596 Cassia laevigata Species 0.000 description 2
• 235000006693 Cassia laevigata Nutrition 0.000 description 2
• 241000701489 Cauliflower mosaic virus Species 0.000 description 2
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
• 101710131740 Docking protein 1 Proteins 0.000 description 2
• 229910052693 Europium Inorganic materials 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 102000025850 HLA-A2 Antigen Human genes 0.000 description 2
• 108010074032 HLA-A2 Antigen Proteins 0.000 description 2
• 101710154606 Hemagglutinin Proteins 0.000 description 2
• 241000238631 Hexapoda Species 0.000 description 2
• 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
• 101000805172 Homo sapiens Docking protein 1 Proteins 0.000 description 2
• 102000014150 Interferons Human genes 0.000 description 2
• 108010050904 Interferons Proteins 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• 102000004889 Interleukin-6 Human genes 0.000 description 2
• 108090001005 Interleukin-6 Proteins 0.000 description 2
• 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
• 229910052765 Lutetium Inorganic materials 0.000 description 2
• 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 2
• 102000000812 NK Cell Lectin-Like Receptor Subfamily K Human genes 0.000 description 2
• 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 description 2
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 108010067902 Peptide Library Proteins 0.000 description 2
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
• 101710182846 Polyhedrin Proteins 0.000 description 2
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
• 102100038358 Prostate-specific antigen Human genes 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 101710176177 Protein A56 Proteins 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 102000001253 Protein Kinase Human genes 0.000 description 2
• 108010039491 Ricin Proteins 0.000 description 2
• 102000014400 SH2 domains Human genes 0.000 description 2
• 108050003452 SH2 domains Proteins 0.000 description 2
• 241000700584 Simplexvirus Species 0.000 description 2
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 108091081024 Start codon Proteins 0.000 description 2
• 108010090804 Streptavidin Proteins 0.000 description 2
• 230000010782 T cell mediated cytotoxicity Effects 0.000 description 2
• WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• 241000723873 Tobacco mosaic virus Species 0.000 description 2
• 102000004357 Transferases Human genes 0.000 description 2
• 108090000992 Transferases Proteins 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 2
• VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 2
• 241000700618 Vaccinia virus Species 0.000 description 2
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
• 108010067390 Viral Proteins Proteins 0.000 description 2
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
• 230000002776 aggregation Effects 0.000 description 2
• 230000000172 allergic effect Effects 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 230000009435 amidation Effects 0.000 description 2
• 238000007112 amidation reaction Methods 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000003042 antagnostic effect Effects 0.000 description 2
• VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 2
• 230000001905 anti-neuroblastoma Effects 0.000 description 2
• 230000000840 anti-viral effect Effects 0.000 description 2
• 230000005875 antibody response Effects 0.000 description 2
• 102000025171 antigen binding proteins Human genes 0.000 description 2
• 108091000831 antigen binding proteins Proteins 0.000 description 2
• 210000000612 antigen-presenting cell Anatomy 0.000 description 2
• 208000010668 atopic eczema Diseases 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 108010005774 beta-Galactosidase Proteins 0.000 description 2
• 238000010256 biochemical assay Methods 0.000 description 2
• 239000012620 biological material Substances 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 238000000423 cell based assay Methods 0.000 description 2
• 230000009134 cell regulation Effects 0.000 description 2
• 230000005889 cellular cytotoxicity Effects 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• 230000004186 co-expression Effects 0.000 description 2
• 230000024203 complement activation Effects 0.000 description 2
• 239000003636 conditioned culture medium Substances 0.000 description 2
• 230000001268 conjugating effect Effects 0.000 description 2
• 239000000470 constituent Substances 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 229940127089 cytotoxic agent Drugs 0.000 description 2
• 239000002254 cytotoxic agent Substances 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 239000003145 cytotoxic factor Substances 0.000 description 2
• 239000002619 cytotoxin Substances 0.000 description 2
• 229960000640 dactinomycin Drugs 0.000 description 2
• 229960000975 daunorubicin Drugs 0.000 description 2
• CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 2
• 238000001212 derivatisation Methods 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 239000012893 effector ligand Substances 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 239000003797 essential amino acid Substances 0.000 description 2
• 235000020776 essential amino acid Nutrition 0.000 description 2
• OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 230000022244 formylation Effects 0.000 description 2
• 238000006170 formylation reaction Methods 0.000 description 2
• UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 229960003180 glutathione Drugs 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 210000002443 helper t lymphocyte Anatomy 0.000 description 2
• 230000003463 hyperproliferative effect Effects 0.000 description 2
• 230000005931 immune cell recruitment Effects 0.000 description 2
• 239000012642 immune effector Substances 0.000 description 2
• 230000006058 immune tolerance Effects 0.000 description 2
• 229940027941 immunoglobulin g Drugs 0.000 description 2
• 229940121354 immunomodulator Drugs 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 206010022000 influenza Diseases 0.000 description 2
• 230000004941 influx Effects 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 229960000367 inositol Drugs 0.000 description 2
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
• 229940079322 interferon Drugs 0.000 description 2
• 230000004068 intracellular signaling Effects 0.000 description 2
• 108010003486 leucyl-leucyl-phenylalanyl-glycyl-tyrosyl-prolyl-valyl-tyrosyl-valine Proteins 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 2
• 239000006166 lysate Substances 0.000 description 2
• 239000011572 manganese Substances 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 230000010534 mechanism of action Effects 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 150000002739 metals Chemical class 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 230000005298 paramagnetic effect Effects 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 230000006320 pegylation Effects 0.000 description 2
• 229960003171 plicamycin Drugs 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
• 238000000159 protein binding assay Methods 0.000 description 2
• 108060006633 protein kinase Proteins 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 238000010188 recombinant method Methods 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000008929 regeneration Effects 0.000 description 2
• 238000011069 regeneration method Methods 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 239000010948 rhodium Substances 0.000 description 2
• 238000013391 scatchard analysis Methods 0.000 description 2
• 239000011669 selenium Substances 0.000 description 2
• 229940124513 senna glycoside Drugs 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 238000002741 site-directed mutagenesis Methods 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 230000003393 splenic effect Effects 0.000 description 2
• 210000004988 splenocyte Anatomy 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• 230000009261 transgenic effect Effects 0.000 description 2
• MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 2
• 229960003048 vinblastine Drugs 0.000 description 2
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
• 229960004528 vincristine Drugs 0.000 description 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
• DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• MNZLMQYCEWHPPS-REOHCLBHSA-N (2s)-2-azaniumyl-5,5,5-trifluoro-4-(trifluoromethyl)pentanoate Chemical compound OC(=O)[C@@H](N)CC(C(F)(F)F)C(F)(F)F MNZLMQYCEWHPPS-REOHCLBHSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• 101710170920 62 kDa protein Proteins 0.000 description 1
• CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 108010066676 Abrin Proteins 0.000 description 1
• 102000012440 Acetylcholinesterase Human genes 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
• 108010000239 Aequorin Proteins 0.000 description 1
• 235000013479 Amaranthus retroflexus Nutrition 0.000 description 1
• 244000055702 Amaranthus viridis Species 0.000 description 1
• 235000004135 Amaranthus viridis Nutrition 0.000 description 1
• 102400000068 Angiostatin Human genes 0.000 description 1
• 108010079709 Angiostatins Proteins 0.000 description 1
• 108090000672 Annexin A5 Proteins 0.000 description 1
• 102000004121 Annexin A5 Human genes 0.000 description 1
• 241000272517 Anseriformes Species 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 102100023927 Asparagine synthetase [glutamine-hydrolyzing] Human genes 0.000 description 1
• 108010070255 Aspartate-ammonia ligase Proteins 0.000 description 1
• 241000182988 Assa Species 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 108060000903 Beta-catenin Proteins 0.000 description 1
• 102000015735 Beta-catenin Human genes 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 238000009631 Broth culture Methods 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• 102000053028 CD36 Antigens Human genes 0.000 description 1
• 102100032937 CD40 ligand Human genes 0.000 description 1
• 241001164374 Calyx Species 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 235000009344 Chenopodium album Nutrition 0.000 description 1
• 235000005484 Chenopodium berlandieri Nutrition 0.000 description 1
• 235000009332 Chenopodium rubrum Nutrition 0.000 description 1
• JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
• VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 241000272194 Ciconiiformes Species 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 241000709687 Coxsackievirus Species 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 101710112752 Cytotoxin Proteins 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 241000725618 Duck hepatitis B virus Species 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 102000001301 EGF receptor Human genes 0.000 description 1
• 108060006698 EGF receptor Proteins 0.000 description 1
• 101150029707 ERBB2 gene Proteins 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
• 108010079505 Endostatins Proteins 0.000 description 1
• 108010055196 EphA2 Receptor Proteins 0.000 description 1
• 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 241000701959 Escherichia virus Lambda Species 0.000 description 1
• 108090000371 Esterases Proteins 0.000 description 1
• 108010020195 FLAG peptide Proteins 0.000 description 1
• XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 108010021472 Fc gamma receptor IIB Proteins 0.000 description 1
• 241000724791 Filamentous phage Species 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 229910052688 Gadolinium Inorganic materials 0.000 description 1
• GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 208000005577 Gastroenteritis Diseases 0.000 description 1
• 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
• 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 108010026389 Gramicidin Proteins 0.000 description 1
• 241000218513 Groundnut rosette virus Species 0.000 description 1
• 108010051696 Growth Hormone Proteins 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 241000606768 Haemophilus influenzae Species 0.000 description 1
• 241000589989 Helicobacter Species 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 101710081758 High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
• 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
• 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
• 229910052689 Holmium Inorganic materials 0.000 description 1
• 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 1
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
• 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 1
• 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 1
• 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
• 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 1
• 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• 241000701806 Human papillomavirus Species 0.000 description 1
• 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
• 101150098499 III gene Proteins 0.000 description 1
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 1
• 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 1
• 108020005350 Initiator Codon Proteins 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 102000014746 Interferon-Stimulated Gene Factor 3 Human genes 0.000 description 1
• 108010064052 Interferon-Stimulated Gene Factor 3 Proteins 0.000 description 1
• 102000000589 Interleukin-1 Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 125000000659 L-selenomethionine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])[Se]C([H])([H])[H] 0.000 description 1
• 108010054278 Lac Repressors Proteins 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 1
• 208000030514 Leukocyte adhesion deficiency type II Diseases 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• 239000012097 Lipofectamine 2000 Substances 0.000 description 1
• 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 102000043129 MHC class I family Human genes 0.000 description 1
• 108091054437 MHC class I family Proteins 0.000 description 1
• PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
• 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
• 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 241000551546 Minerva Species 0.000 description 1
• VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
• 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
• 206010027926 Monoplegia Diseases 0.000 description 1
• 101000913071 Mus musculus Low affinity immunoglobulin gamma Fc region receptor II Proteins 0.000 description 1
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 241000588653 Neisseria Species 0.000 description 1
• 241000714209 Norwalk virus Species 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• 108091005461 Nucleic proteins Chemical group 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 241001425800 Pipa Species 0.000 description 1
• 102000013566 Plasminogen Human genes 0.000 description 1
• 108010051456 Plasminogen Proteins 0.000 description 1
• 229920000388 Polyphosphate Polymers 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 229910052777 Praseodymium Inorganic materials 0.000 description 1
• 229910052773 Promethium Inorganic materials 0.000 description 1
• 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
• 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
• 241000711798 Rabies lyssavirus Species 0.000 description 1
• 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 description 1
• 108050004017 Ras GTPase-activating protein 1 Proteins 0.000 description 1
• 241000725643 Respiratory syncytial virus Species 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 241000702670 Rotavirus Species 0.000 description 1
• KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
• MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical class O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
• AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
• 241000235070 Saccharomyces Species 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 229910052772 Samarium Inorganic materials 0.000 description 1
• 101710204410 Scaffold protein Proteins 0.000 description 1
• 101710146343 Scaffold protein D13 Proteins 0.000 description 1
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
• 241000607764 Shigella dysenteriae Species 0.000 description 1
• 102100038803 Somatotropin Human genes 0.000 description 1
• 241000256251 Spodoptera frugiperda Species 0.000 description 1
• 241000191940 Staphylococcus Species 0.000 description 1
• 241000191967 Staphylococcus aureus Species 0.000 description 1
• 241000193998 Streptococcus pneumoniae Species 0.000 description 1
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
• 101000930762 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) Signal recognition particle receptor FtsY Proteins 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 102000000551 Syk Kinase Human genes 0.000 description 1
• 108010016672 Syk Kinase Proteins 0.000 description 1
• 230000006044 T cell activation Effects 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 210000003592 T-IEL Anatomy 0.000 description 1
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
• 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 1
• 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 1
• SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
• 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 101150042088 UL16 gene Proteins 0.000 description 1
• GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
• 229910052770 Uranium Inorganic materials 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 241000607626 Vibrio cholerae Species 0.000 description 1
• 229910052769 Ytterbium Inorganic materials 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
• ZSZXYWFCIKKZBT-ZVDPZPSOSA-N [(2r)-3-[[(2s,3s,5r,6s)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O ZSZXYWFCIKKZBT-ZVDPZPSOSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000004308 accommodation Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 238000007818 agglutination assay Methods 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 239000013566 allergen Substances 0.000 description 1
• 239000000956 alloy Substances 0.000 description 1
• 229910045601 alloy Inorganic materials 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 238000004873 anchoring Methods 0.000 description 1
• 229960003473 androstanolone Drugs 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
• 238000003149 assay kit Methods 0.000 description 1
• 244000309743 astrovirus Species 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 102000005936 beta-Galactosidase Human genes 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000001851 biosynthetic effect Effects 0.000 description 1
• 229910052797 bismuth Inorganic materials 0.000 description 1
• JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 230000009460 calcium influx Effects 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 125000000837 carbohydrate group Chemical group 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 231100000357 carcinogen Toxicity 0.000 description 1
• 239000003183 carcinogenic agent Substances 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 238000002659 cell therapy Methods 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 230000007541 cellular toxicity Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229910052804 chromium Inorganic materials 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 229910017052 cobalt Inorganic materials 0.000 description 1
• 239000010941 cobalt Substances 0.000 description 1
• GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
• 238000002288 cocrystallisation Methods 0.000 description 1
• 229960001338 colchicine Drugs 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 201000010989 colorectal carcinoma Diseases 0.000 description 1
• 230000009137 competitive binding Effects 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 238000002967 competitive immunoassay Methods 0.000 description 1
• 150000001875 compounds Chemical class 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 230000004940 costimulation Effects 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
• GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
• 231100000409 cytocidal Toxicity 0.000 description 1
• 230000000445 cytocidal effect Effects 0.000 description 1
• 238000004163 cytometry Methods 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 230000001085 cytostatic effect Effects 0.000 description 1
• 238000002784 cytotoxicity assay Methods 0.000 description 1
• 231100000263 cytotoxicity test Toxicity 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 238000001784 detoxification Methods 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• 230000006334 disulfide bridging Effects 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 238000002592 echocardiography Methods 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
• 229960002694 emetine Drugs 0.000 description 1
• AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
• 201000002491 encephalomyelitis Diseases 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 230000002327 eosinophilic effect Effects 0.000 description 1
• 125000004185 ester group Chemical group 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 239000012997 ficoll-paque Substances 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 238000007421 fluorometric assay Methods 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 210000002683 foot Anatomy 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 229910052733 gallium Inorganic materials 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 230000004545 gene duplication Effects 0.000 description 1
• 229910052732 germanium Inorganic materials 0.000 description 1
• GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
• 102000005396 glutamine synthetase Human genes 0.000 description 1
• 108020002326 glutamine synthetase Proteins 0.000 description 1
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
• 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
• XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 210000000224 granular leucocyte Anatomy 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 239000000185 hemagglutinin Substances 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
• 239000000710 homodimer Substances 0.000 description 1
• 102000044042 human KLRK1 Human genes 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• RWSOTUBLDIXVET-UHFFFAOYSA-M hydrosulfide Chemical compound [SH-] RWSOTUBLDIXVET-UHFFFAOYSA-M 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000003100 immobilizing effect Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 238000011502 immune monitoring Methods 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000000951 immunodiffusion Effects 0.000 description 1
• 108010023260 immunoglobulin Fv Proteins 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 229910052738 indium Inorganic materials 0.000 description 1
• APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 230000006749 inflammatory damage Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 102000030582 inositol polyphosphate 5-phosphatase Human genes 0.000 description 1
• 108060004006 inositol polyphosphate 5-phosphatase Proteins 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 229940100601 interleukin-6 Drugs 0.000 description 1
• 201000002313 intestinal cancer Diseases 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 230000007709 intracellular calcium signaling Effects 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
• 210000001821 langerhans cell Anatomy 0.000 description 1
• 229910052746 lanthanum Inorganic materials 0.000 description 1
• FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
• 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 238000003754 machining Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 229910052748 manganese Inorganic materials 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 238000012737 microarray-based gene expression Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 229960005485 mitobronitol Drugs 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
• 239000003147 molecular marker Substances 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 229910052750 molybdenum Inorganic materials 0.000 description 1
• 239000011733 molybdenum Substances 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 210000004980 monocyte derived macrophage Anatomy 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
• ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
• 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 230000017764 negative regulation of mast cell activation Effects 0.000 description 1
• 230000007514 neuronal growth Effects 0.000 description 1
• 230000036963 noncompetitive effect Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 230000008816 organ damage Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 239000005022 packaging material Substances 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 244000045947 parasite Species 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 210000004976 peripheral blood cell Anatomy 0.000 description 1
• 210000003024 peritoneal macrophage Anatomy 0.000 description 1
• 102000013415 peroxidase activity proteins Human genes 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 150000003905 phosphatidylinositols Chemical class 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 239000001205 polyphosphate Substances 0.000 description 1
• 235000011176 polyphosphates Nutrition 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 239000004800 polyvinyl chloride Substances 0.000 description 1
• 229920000915 polyvinyl chloride Polymers 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• VQMWBBYLQSCNPO-UHFFFAOYSA-N promethium atom Chemical compound [Pm] VQMWBBYLQSCNPO-UHFFFAOYSA-N 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• VYXXMAGSIYIYGD-NWAYQTQBSA-N propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(pyrimidine-4-carbonylamino)phosphoryl]amino]-2-methylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)NP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)NC(=O)c1ccncn1 VYXXMAGSIYIYGD-NWAYQTQBSA-N 0.000 description 1
• 229960003712 propranolol Drugs 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 230000004853 protein function Effects 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 239000012264 purified product Substances 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 238000000163 radioactive labelling Methods 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000012121 regulation of immune response Effects 0.000 description 1
• 230000027404 regulation of phosphorylation Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 230000019254 respiratory burst Effects 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 229930002330 retinoic acid Natural products 0.000 description 1
• 229910052702 rhenium Inorganic materials 0.000 description 1
• WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 229910052703 rhodium Inorganic materials 0.000 description 1
• MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
• 102200081893 rs137854510 Human genes 0.000 description 1
• 229910052707 ruthenium Inorganic materials 0.000 description 1
• KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
• 229910052706 scandium Inorganic materials 0.000 description 1
• SIXSYDAISGFNSX-UHFFFAOYSA-N scandium atom Chemical compound [Sc] SIXSYDAISGFNSX-UHFFFAOYSA-N 0.000 description 1
• 230000002000 scavenging effect Effects 0.000 description 1
• 239000013606 secretion vector Substances 0.000 description 1
• 229910052711 selenium Inorganic materials 0.000 description 1
• 210000000582 semen Anatomy 0.000 description 1
• 230000001235 sensitizing effect Effects 0.000 description 1
• 238000007493 shaping process Methods 0.000 description 1
• 229940007046 shigella dysenteriae Drugs 0.000 description 1
• 230000007727 signaling mechanism Effects 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 229910052712 strontium Inorganic materials 0.000 description 1
• CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 229910052713 technetium Inorganic materials 0.000 description 1
• GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 238000012956 testing procedure Methods 0.000 description 1
• 229960002372 tetracaine Drugs 0.000 description 1
• GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
• 229910052716 thallium Inorganic materials 0.000 description 1
• BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 230000001732 thrombotic effect Effects 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
• ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
• HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
• 230000004222 uncontrolled growth Effects 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 229940118696 vibrio cholerae Drugs 0.000 description 1
• 210000002845 virion Anatomy 0.000 description 1
• 239000011534 wash buffer Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 210000002268 wool Anatomy 0.000 description 1
• 229910052724 xenon Inorganic materials 0.000 description 1
• FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
• NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1
• VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1